17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes
Aleksandra Mielczarek-Lewandowska(Medical University of Lodz), Mariusz L. Hartman(Medical University of Lodz)
Cited by 20
Related Papers
Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells
|Laboratory Investigation|2017|32
17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines
|International Journal of Molecular Sciences|2020|17